BMY241227P70000
- 11.75
- 0.000.00%
Bristol-Myers Squibb Newsroom
Weekly Buzz: So far, Santa is Letting us Down
So Much For The Man With the Bag | Wall Street Today
Bristol-Myers Squibb's Opdivo Qvantig Gets US FDA Approval
Express News | FDA Approves Nivolumab and Hyaluronidase-Nvhy for Subcutaneous Injection
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Bristol-Myers Squibb Says Phase 3 Trials of Sotyktu in Psoriatic Arthritis Meets Endpoints
Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials
Express News | Bristol-Myers Squibb Co: Sotyktu Was Well-Tolerated and Demonstrated Safety Consistent With Established Profile
Express News | Bristol-Myers Squibb Co - Phase 3 Trials Met Primary Endpoint With Significant Acr20 Response
Express News | Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu (Deucravacitinib) in Adults With Psoriatic Arthritis
Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Express News | Bristol Myers Squibb Receives European Commission Approval for Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) for the First-Line Treatment of Adult Patients With Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
J.P. Morgan Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $70
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game